PORTLAND, Ore., October 22, 2020 – Nobilis Therapeutics announced today the issuance of a US Patent (US Patent No: 10,792,305 B2) for a patent titled “Therapeutic immune modulation using noble gas compositions.” One of it broadest claims includes “a method of treating an autism spectrum disorder comprising the steps of: a) identifying a patient with an autism spectrum disorder; and b) administering a noble gas containing composition comprising oxygen and/or air and a proportion by volume of 20 to 70% of a noble gas at a sufficient concentration and frequency in a patient in need thereof to effectively treat said autism spectrum disorder.”
“Together with our recently published data on the positive effects in an animal model of autism this patent adds tremendous value to the breadth of future label for our drug-device combination,” said Dr. Vlad Bogin, CEO of Nobilis Therapeutics. “While we don’t know the exact mechanism by which our drug may be exerting its beneficial effects in ASD, we suspect that its anti-inflammatory and immunomodulatory properties coupled with a multimodal effect on the excitatory-inhibitory balance within the CNS are playing a role,” continued Dr. Bogin.
The company plans to submit grant applications to conduct additional preclinical studies in this field.
About Nobilis Therapeutics, Inc.
Nobilis Therapeutics is a biotechnology company that is focused on development and commercialization of proprietary inhalation-based treatments using portable device for controlled administration of inert gases. The Company has filed multiple patents on the use of inert gases for treatment of a variety of psychiatric, neurodegenerative and other diseases and leverages the experience of its international team that has studied this technology in the treatment of over 3000 patients for conditions ranging from panic attacks to substance abuse. Company’s first clinical trial in 81 patients with Panic Disorder showed significant signals of efficacy. In 2016 the Company entered an exclusive licensing agreement with Harvard University on the use of NBTX-001 in PTSD and had a patent issued the following year. Of its 14 independently filed patents 4 have been issued. In January of 2019 the Company had entered collaboration with Linde AG to support its medical device and clinical development programs. In December of 2019 the company cleared an IND to run a phase 2b trial in patients with PTSD and in July of 2020 the company cleared its second IND allowing it to commence a phase 2b trial in patients with Panic Disorder.
Vlad Bogin, MD, FACP
US Bancorp Tower,
111 S.W. Fifth Avenue, Suite 3150,
Portland, OR, 97204
Tel: (971) 229-1679